See editorial on page 756. H epatocellular carcinoma (HCC) is the fifth most common cancer and the second most common cause of cancer-related mortality in the world. 1 It has been increasing worldwide and has nearly tripled in the last decades in the Unites States. 2, 3 Etiologic and clinical heterogeneity in HCC populations has hampered efforts in establishing a universally adopted treatment scheme to improve patient care. An ideal staging system would be able to provide accurate prognosis, stratify patients into distinct prognostic groups, and suggest up-to-date therapeutic strategies. 4 The uniquely challenging aspect of staging HCC is the interplay of 2 diseases, liver cirrhosis and cancer. 5, 6 Liver cirrhosis ultimately results in reduced liver function and can lead to cancer. Cancer in turn worsens liver function by mass effect and parenchymal invasion. Staging is further complicated by patient's social history and comorbidities often relevant in this patient population. There has been at least 8 proposed HCC staging systems, including the Barcelona Clinic Liver Cancer (BCLC) staging system. 7 The BCLC staging system is currently the most widely used system in Europe and the Unites States given its comprehensive algorithm tied to treatment recommendations. It has been externally validated and provides a common framework to enable comparison between patient cohorts and institutions. [7] [8] [9] [10] However, BCLC staging often draws criticism because of conservative treatment recommendations in patients for whom aggressive treatment approaches have become commonplace due to technical safety and effectiveness. [11] [12] [13] [14] [15] Although widely quoted in the scientific literature, efforts have been underway to modify and update the BCLC staging.
The recently developed Hong Kong Liver Cancer (HKLC) staging system has garnered international attention because of its comprehensive nature, based on the largest patient cohort to date for HCC staging, and tied to treatment recommendations that addresses the aforementioned limitations of the BCLC system. 16 Compared with BCLC, HKLC staging system provided superior survival discrimination in their internal validation cohort. However, the 3958 patients in the HKLC study were mainly Asians with hepatitis B virus (HBV). Hence, the authors called for external validation outside of Asia, where there are more heterogeneous causes of HCC. 16 The purpose of our study is to assess the external prognostic validity and clinical use of the recently developed HKLC staging system in a North American population with unresectable HCC and compare the performance with the BCLC system.
Methods

Patient Population
This institutional review board-approved and Health Insurance Portability and Accountability Act-compliant study was performed at a single tertiary referral hospital in North America (Johns Hopkins Hospital, Baltimore, MD). A total of 1009 consecutive HCC patients derived from an ongoing database tracking HCC patients from 2000 to 2014 and who underwent at least 1 intraarterial therapy (IATs) (ethiodized oil, drug-eluting beads, or radioembolization) with or without systemic chemotherapy, liver transplantation, resection, and/or ablation were included. 17 A total of 131 patients (representing 13.0% of total) had missing laboratory or radiologic data that prevented calculation of either HKLC or BCLC stages. A complete-case analysis was performed. A comprehensive review of medical charts, imaging, and outcomes were included in the database.
Treatment Criteria and Modality
The diagnosis of HCC was made by imaging appearance and/or by biopsy as defined by guidelines. 9, [18] [19] [20] Patients with newly diagnosed HCC referred to our center were discussed at weekly multidisciplinary conference for treatment decision. Patients eligible for immediately curative treatments were routed to the corresponding specialties. The remaining patients ineligible for immediate curative therapy were considered for IAT AE sorafenib, transplantation, and/or delayed resection/ablation as part of individualization of patient care; these were often outside of BCLC treatment guidelines. The cohort consisted of mainly unresectable HCC that included liver transplantation candidates undergoing bridging using IAT, questionably resectable candidates undergoing down-staging with IAT, and select BCLC D patients.
Most patients underwent transarterial chemoembolization (TACE) in this cohort. For conventional TACE, a mixture of ethiodized oil, doxorubicin (Adriamycin; Pharmacia & Upjohn, Kalamazoo, MI), mitomycin-C (Bedford Laboratories, Bedford, OH), and cisplatin (Bristol-Myers Squibb, Princeton, NJ) was injected in the hepatic arterial vasculature through a microcatheter. This was followed by injection of up to 4 mL of 100-to-300-mm microsphere particles (Embosphere; Biosphere Medical, Boston, MA). For TACE with drug-eluting beads, patients received 2 mL of 100-to-300-mm-diameter microsphere particles (LC Beads; BioCompatibles, Surrey, England) loaded with 50 mg of doxorubicin hydrochloride (25 mg/mL) and mixed with nonionic contrast material (300 mg of iodine per milliliter, Oxilan; Guerbet, Bloomington, IN). 21 
Study Design and Data Analysis
The TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis) checklist was adopted to ensure accuracy and comprehensiveness of the external validity assessment. 22 The HKLC staging scheme is shown in Figure 1 . 16 HKLC staging with 5 major classifications (stages I, II, III, IV, V; here referred as HKLC-5) and the full 9 subclassifications (stages I, IIa, IIb, IIIa, IIIb, IVa, IVb, Va, and Vb; here referred as HKLC-9) were considered. All laboratory values were taken from the time immediately before the first IAT session at our institution. Treatment information was gathered from structured data and freestyle clinician notes in the institutional electronic medical record. The outcome of interest, overall survival (OS), was computed from the date of first IAT at our institution to death or last known clinic follow-up. OS was ascertained by 2 methods. First, the institutional electronic medical record was checked to confirm patient's vital status and death date if available. Second, all patients with unknown vital status were queried once on the US Office of Vital Records registry in late 2014. All patients who were alive or had unknown vital status were censored on the last known clinical follow-up date. Kaplan-Meier survival curves were plotted and the log-rank test was used to assess the significance of the survival curve separation. 23, 24 A difference with a 2-tailed P value of < .05 was considered statistically significant.
Model calibration, discrimination, reduction in error, monotonicity of gradient, and homogeneity were reported as important measures of staging system performance. [25] [26] [27] [28] Measurement of discrepancy between observed and predicted OS time was made through calibration plots of validation cohort versus original HKLC predictions. 29 The ability of the staging system to assign distinct stages to patient groups with different survival was measured using Harrell C statistic, a rank-order statistic that relates to the area under the receiver operating characteristic curve. 30 Akaike information criterion from the Cox proportional hazards model was used to further confirm survival discrimination. 31 Each staging system's ability to reduce error in predicting survival time was calculated as previously reported in literature. 32 Cox model with likelihood ratio chi-square test was used to measure homogeneity and monotonicity of gradients. 24 Monotonicity of gradient was calculated to measure the consistency of worsening patient survival with worsening stages. 25 Homogeneity was used to measure similarity in patient survival within a given stage. 25 Greater C statistic, reduction in error, and likelihood ratio chi-square values corresponded to better staging system performance, whereas the opposite was the case for Akaike information criterion.
Analysis was performed in the full cohort and some in subcohorts with HBV carriers and hepatitis C virus (HCV) carriers to assess any clinically relevant trends in different subgroups. Pre-and post-2008 subgroup analysis was performed to assess for temporal validity. Further subgroup analysis of only confirmed dead patients on pre-and post-2008 subcohorts was done to explore the effect of censoring. The full validation cohort was primarily analyzed for comparison with the original HKLC cohort, whereas both HBV and HCV subcohorts were primarily analyzed for comparison with the full validation cohort. All statistical analysis and plotting were done in R: Statistical Programming Language Version 3.8.11 (Vienna, Austria) and Microsoft Excel 2010 (Redmond, WA). 16 EVM, extrahepatic vascular invasion or distant metastasis. 
Results
Validation Cohort and Survival Information
A total of 881 patients were included in the full validation cohort. Detailed baseline clinicopathologic characteristics are summarized in Table 1 . Notable distinguishing characteristics of this validation cohort from the original development cohort was the predominance of white (n ¼ 520; 59.0%) male (n ¼ 698; 79.2%) patients with HCV (n ¼ 427; 48.5%) and alcohol (n ¼ 269; 30.5%) as major HCC etiologies. Other major characteristics of this cohort included Eastern Cooperative Oncology Group (ECOG) performance score 0 (n ¼ 426; 48.4%) and Child-Pugh Class A (n ¼ 534; 60.6%) ( Table 1 ). All patients received conventional TACE (n ¼ 534; 60.6%), TACE with drug-eluting beads (n ¼ 326; 37.0%), or radioembolization with yttrium-90 (n ¼ 21; 2.4%). One-third of the patients received treatment using liver transplantation, resection, or sorafenib at some point in the treatment course.
The full validation cohort on average had slightly more advanced disease compared with the original HKLC cohort, 16 with smaller proportions of Child-Pugh A (60.6% vs 72.6%, validation cohort vs the original HKLC cohort, respectively), ECOG performance score 0 (48.4% vs 56.9%, respectively), patients with tumor size <2 cm (7.0% vs 9.3%, respectively), and patients with a solitary nodule (30.6% vs 47.3% respectively) ( Table 1) . There was larger presence in our study of BCLC C patients (60.8% vs 39.1% for the original HKLC cohort) ( Table 2) .
Median OS (mOS), as calculated from first IAT date at our institution to date of death or censorship, for the entire cohort across all stages was 9.8 months. Detailed mOS information and the number of patients corresponding to each stage for BCLC, HKLC-5, and HKLC-9 are reported in Table 2 . Three most represented groups in cross-tabulations were HKLC III/BCLC C patients (n ¼ 193; 21.9%), HKLC IV/BCLC C (n ¼ 162; 18.3%), and HKLC II/BCLC C (n ¼ 145; 16.5%) (Supplementary Table 1 ).
Prognostic Validation
HKLC and BCLC staging systems predicted survival with significance (P < .001). Specifically, BCLC and HKLC-5 staging achieved separation of the survival curves (Figure 2A and B) , whereas the survival curves for HKLC-9 had overlaps in survival for stages IIIa, IIIb, IVa, and Va, all of which had mOS of approximately 11 months ( Figure 2C ).
Both calibration curves for HKLC-5 and HKLC-9 demonstrated matching of OS between the validation cohort and the original cohort (Figure 3 ). Both plots result in R 2 values >0.9 signifying goodness of fit, with HKLC-5 (R 2 ¼ 0.95) being slightly better than HKLC-9 (R 2 ¼ 0.90). HKLC-5 and HKLC-9 demonstrated stronger survival discrimination than BCLC as illustrated by both Harrell C statistic and Akaike information criterion (Table 3) . Greater homogeneity was observed with HKLC compared with BCLC (Table 3) , suggesting similar OS within each given stage. The sum of errors in survival prediction for the entire cohort when using mOS as the sole survival predictor was 782 days. Compared with using the mOS alone, when using the BCLC staging as the survival predictor, 12% overall error reduction was observed, whereas greater error reductions of 14% and 16% were measured using HKLC-5 and HKLC-9, respectively (Table 3) .
Subcohort Analysis: Hepatitis B Virus Versus Hepatitis C Virus and Pre-2008 Versus Post-2008
The predominant population in the HBV subcohort was an Asian (n ¼ 49; 37.1%), male (n ¼ 111; 85.1%) patient with ECOG performance score 0 (n ¼ 66; 50.0%), and Child-Pugh Class A (n ¼ 90; 68.2%) ( Table 1) . Predominant patient characteristics in the HCV subcohort was white (n ¼ 232; 54.3%), male (n ¼ 349; 81.7%), ECOG performance score 0 (n ¼ 217; 50.8%), and Child-Pugh Class A (n ¼ 240; 56.2%) ( Table 1) . Overall, the survival curves demonstrate similar qualitative degree of separation among HBV and HCV cohorts, although with some more overlaps, possibly caused by smaller sample size in each stage in this subcohort compared with the full validation cohort ( Table 2 discrimination and error reduction in various subcohorts. The subcohorts demonstrated consistent worsening of survival with worsening stages, similar to the full validation cohort, as expected of a staging system (Table 3) .
Discussion
The present study showed prognostic external validity of the HKLC staging system in a North American HCC cohort whose main treatment modality was TACE and primary HCC etiology was HCV and/or ETOH. Specifically, the HKLC-5 staging demonstrated significantly improved performance over BCLC based on calibration, discrimination, monotonicity/homogeneity, and survival curve separation. Furthermore, HKLC-5 identified stages IV and V patients who had very poor survival despite IAT. In light of the superior predictive power and more practically relevant treatment decision support, the HKLC staging system may have a significant impact on HCC patient stratification for research design, clinical decision recommendation, and patient care.
External prognostic validation is an important step in staging system establishment because prediction models almost always perform better on the development cohort. 33 Furthermore, validation process allows assessment of model robustness in a new patient cohort where underlying assumptions, such as patient demographics, treatment strategy, and disease etiology, are violated by measurable amounts.
Asian and North American HCC cohorts have key differences in treatment strategies, etiologic factors, and socioeconomic background. Measurable differences included disease etiology and baseline patient characteristics. Unmeasured differences include patient social history and medical comorbidity that could have influence on prognosis but are difficult to quantify in a research study. Hence, the value of staging system validation in an independent cohort cannot be overstated.
The treatment course for patients with HCC is often driven by availability of local expertise, which is mainly TACE at our institution (>70% of patients with HCC). Compared with the original HKLC cohort, our validation cohort had fewer small-sized (<2 cm) single patients with HCC, especially those classified as Child-Pugh Class A. This is because a large number of very early stage patients proceeded to ablation or resection without requiring IAT. Furthermore, it explains why our validation cohort had percent-wise higher proportion of BCLC C patients and slightly lower mOS compared with the development cohort. Similar to the development cohort, however, the validation cohort consisted of a wide variety of patients ranging from BCLC A to D and HKLC I to V. A large number of patients in our validation cohort and those who received IATs in the original HKLC cohort were BCLC C patients for whom systemic chemotherapy was recommended per BCLC scheme.
An important secondary finding from this study is the HKLC system's identification of patient groups who did not seem to benefit from current treatment strategy. HKLC stages IV and V had uniformly poor survival at 6 months and 4 months, respectively. A large percentage of patients in this cohort were treated with TACE, hence very poor survival in these 2 stages implicate TACE should not be used in this particular group. Consequently, an important benefit of the HKLC system may be the identification of exclusion criteria for IAT. The 9.8 months mOS for the full validation cohort seemed particularly poor compared with other studies, but explained by difference in mOS calculation methodology (ie, start from first IAT date instead of first imaging/ pathology diagnosis).
Furthermore, temporal validity of BCLC and HKLC as shown in Supplementary Figure 1 There were several limitations to our study. First, all patients in this validation cohort underwent IAT at some point in the treatment course. This underrepresented resectable HCC cases and primary advanced/metastatic cases that were determined ineligible for IAT and treated with systemic chemotherapy only. However, >70% of patients with HCC received IAT at some point in their treatment course at our institution, in conjunction with resection, transplantation, and systemic chemotherapy. Furthermore, accurate staging would arguably be of greatest relevance in unresectable HCC cases. Second, this is a single-institution study at a tertiary center subject to referral bias. Further study in community setting would be beneficial. Third, the study had high proportion of censored patients (36.4%), including those with incomplete survival data, which resulted in increased variance and potential bias. Despite the stated limitations, HKLC staging system's demonstrated external prognostic validity has important implications. As in this North American study, in 3 patient cohorts of more than 5000 patients from Europe and Asia, HKLC outperformed BCLC as a survival classification system in 2 of the 3 cohorts and similarly performed to BCLC in 1 cohort. 16, 34, 35 The HKLC might become the first HCC staging system accepted across the West and the East, for the purposes of patient stratification for research studies, accurate prediction of patient prognosis, and clinical decision support.
Conclusions
HKLC-5 demonstrated the best combination of performances in survival separation, calibration, and discrimination, while consistently outperforming BCLC staging as a prognostic classification system in this cohort. Furthermore, HKLC identified stages IV and V patients who are unlikely to benefit from IAT.
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